RSS

Crohn's disease

Biopharmaceutical company, TiGenix, has submitted responses to the marketing authorisation application for Cx601, a treatment of complex perianal fistulas in Crohn’s disease patients as a first indication. more

May 31, 2017 2:01 PM News